Αποτελέσματα Αναζήτησης
2 Ιουν 2018 · Clostridium difficile is the leading cause of nosocomial infectious diarrhea. New treatment strategies are needed. In this letter, preliminary data on fecal therapy as primary treatment are...
- Clostridium Difficile Infection
Clostridium difficile is an anaerobic gram-positive,...
- Clostridium Difficile Infection
Despite lack of regulatory approval, fecal microbiota transplantation (FMT) is widely performed to manage C. difficile infection (CDI), particularly recurrent CDI. Herein, we critically review the available randomized controlled trials of FMT and address the following questions: Is FMT better than d …
LJB Fecal transplantation has been used primarily for treatment of C. difficile infection, but studies are needed to determine whether fecal transplantation is an effective treatment for other diseases. Clinicians have limited experience using fecal transplantation for a variety of gastroenterologic diseases—including ulcerative colitis ...
Risk Factors for C difficile Infection. The major identified risk factor for CDI is antibiotic use. CDI is responsible for up to 30% of antibiotic-associated diarrhea. 31 Antibiotics lead to dysbiosis, characterized by decreased diversity of the colonic microbiota.
23 Δεκ 2021 · The donor stool microbiota competes with C. difficile bacteria in recipient gut, allowing for restoration of secondary bile acids and stimulation of the mucosal immune system to help reinstate the microbiome of the patient. 13,14 A prospective study conducted by Barberio et al. analyzed stool samples for metagenomic analysis pre- and post-FMT ...
FMT is now an accepted therapeutic modality for Clostridium difficile infection (CDI), with interest in treatment of other diseases related to alterations in gut microbiota on the horizon as well, such as with ulcerative colitis, metabolic syndrome, hepatic encephalopathy, and irritable bowel syndrome.
21 Σεπ 2022 · In patients with first or second C difficile infection, first-line faecal microbiota transplantation is highly effective and superior to the standard of care vancomycin alone in achieving sustained resolution from C difficile.
